High Throughput Screening Of Novel Protein TherapeuticsSource: INTEGRA Biosciences
Integrating an INTEGRA VIAFLO 96 multichannel pipette into their high throughput expression facility has enabled Molecular Partners (Zurich, Switzerland) to streamline the discovery and development of a novel class of targeted protein therapeutics termed DARPins.
DARPins are a next generation of protein therapeutics combining the advantages of antibodies and small molecule drugs. High target specificity and potency, small size, cost-effective production and a whole range of possible multi-specific format choices gives them the potential to surpass existing antibody drugs and revolutionize protein therapeutics.
Andreas Lehmann, an Expert Technical Assistant working in Molecular Partners 96-well high throughput expression facility commented...